Different involvement of the megakaryocytic lineage by the JAK2^V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis

By Hussein Kais   Brakensiek Kai   Buesche Guntram   Buhr Thomas   Wiese Birgitt   Kreipe Hans   Bock Oliver  

Annals of Hematology, Vol. 86, Iss. 4, 2007-04 ,pp. : 245-253

Springer Publishing Company

Access to resources Recommend Favorite

Expression analysis of microRNA‐125 in patients with polycythemia vera and essential thrombocythemia and correlation with JAK2 allele burden and laboratory findings

By  

International Journal Of Laboratory Hematology, Vol. 37, Iss. 5, 2015-10 ,pp. : 661-667

John Wiley & Sons Inc

Access to resources Recommend Favorite

Biomarker analysis in polycythemia vera under interferon-alpha treatment: clonality, EEC, PRV-1, and JAK2 V617F

By Steimle C.   Lehmann U.   Temerinac S.   Goerttler Ph.   Kreipe H.   Meinhardt G.   Heimpel H.   Pahl H.  

Annals of Hematology, Vol. 86, Iss. 4, 2007-04 ,pp. : 239-244

Springer Publishing Company

Access to resources Recommend Favorite

Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission

By Larsen Thomas Stauffer   Møller Michael Boe   de Stricker Karin   Nørgaard Peter   Samuelsson Jan   Marcher Claus   Andersen Morten T.   Bjerrum Ole Weis   Hasselbalch Hans Carl  

Hematology, Vol. 14, Iss. 6, 2009-12 ,pp. : 331-334

Maney Publishing

Access to resources Recommend Favorite

Treatment related changes in antifibrinolytic activity in patients with polycythemia vera

By Sonmez Mehmet   Saglam Fatma   Karahan S. Caner   Erkut Nergiz   Mentese Ahmet   Sonmez Bircan   Ucar Fahri   Topbas Murat   Ovali Ercument  

Hematology, Vol. 15, Iss. 6, 2010-12 ,pp. : 391-396

Maney Publishing

Access to resources Recommend Favorite